Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 24, 2007

Verus Could Earn $310M through Divestiture of Pediatric Asthma Programs to AstraZeneca

  • AstraZeneca acquired Verus Pharmaceuticals’ pediatric asthma development programs for $30 million. Verus will also receive development expense reimbursements and a potential earn-out payment of $280 million.

    Verus, a pediatric-oriented company, plans to refocus on developing therapeutics for unmet needs associated with related atopic diseases and conditions, comments Robert Keith, president and COO of the company.

    Through the transaction, AstraZeneca will gain North American rights to a Captisol® enabled budesonide solution, a short-acting beta agonist therapy, and a customized version of eFlow® for use with both medications.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »